DK3145488T3 - Flydende farmaceutiske forbindelse - Google Patents

Flydende farmaceutiske forbindelse Download PDF

Info

Publication number
DK3145488T3
DK3145488T3 DK15723695.1T DK15723695T DK3145488T3 DK 3145488 T3 DK3145488 T3 DK 3145488T3 DK 15723695 T DK15723695 T DK 15723695T DK 3145488 T3 DK3145488 T3 DK 3145488T3
Authority
DK
Denmark
Prior art keywords
liquid pharmaceutical
pharmaceutical compound
compound
liquid
pharmaceutical
Prior art date
Application number
DK15723695.1T
Other languages
English (en)
Inventor
Gianluca Rinaldi
Silvia Fratarcangeli
Rio Alessandra Del
Original Assignee
Fresenius Kabi Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50774706&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3145488(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fresenius Kabi Deutschland Gmbh filed Critical Fresenius Kabi Deutschland Gmbh
Application granted granted Critical
Publication of DK3145488T3 publication Critical patent/DK3145488T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK15723695.1T 2014-05-23 2015-05-15 Flydende farmaceutiske forbindelse DK3145488T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14169755.7A EP2946767B1 (en) 2014-05-23 2014-05-23 Liquid pharmaceutical composition
PCT/EP2015/060818 WO2015177059A1 (en) 2014-05-23 2015-05-15 Liquid pharmaceutical composition

Publications (1)

Publication Number Publication Date
DK3145488T3 true DK3145488T3 (da) 2020-08-10

Family

ID=50774706

Family Applications (3)

Application Number Title Priority Date Filing Date
DK15723695.1T DK3145488T3 (da) 2014-05-23 2015-05-15 Flydende farmaceutiske forbindelse
DKBA202000030U DK202000030Y3 (da) 2014-05-23 2020-04-08 Væskeformig farmaceutisk sammensætning
DKBA202000038U DK202000038Y3 (da) 2014-05-23 2020-05-14 Væskeformig farmaceutisk sammensætning

Family Applications After (2)

Application Number Title Priority Date Filing Date
DKBA202000030U DK202000030Y3 (da) 2014-05-23 2020-04-08 Væskeformig farmaceutisk sammensætning
DKBA202000038U DK202000038Y3 (da) 2014-05-23 2020-05-14 Væskeformig farmaceutisk sammensætning

Country Status (18)

Country Link
US (2) US10426833B2 (da)
EP (4) EP2946767B1 (da)
JP (3) JP2017516848A (da)
CN (2) CN111939257A (da)
AU (3) AU2015263247A1 (da)
CA (2) CA2948746C (da)
CY (1) CY1124493T1 (da)
DK (3) DK3145488T3 (da)
ES (2) ES2607489T3 (da)
HK (1) HK1231391A1 (da)
HR (1) HRP20201242T1 (da)
HU (1) HUE050779T2 (da)
IL (2) IL277241B (da)
LT (1) LT3145488T (da)
PT (1) PT3145488T (da)
RS (1) RS60801B1 (da)
SI (1) SI3145488T1 (da)
WO (1) WO2015177059A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
PT2946765T (pt) 2014-05-23 2016-11-10 Ares Trading Sa Composição farmacêutica líquida
CN105543204A (zh) * 2015-12-30 2016-05-04 海口奇力制药股份有限公司 一种组合物及其应用、含有该组合物的稳定剂
US10052296B2 (en) 2016-04-07 2018-08-21 Nevakar Inc. Formulations for treating pain
US11639391B2 (en) * 2017-04-18 2023-05-02 Dr. Reddy's Laboratories Limited Stable liquid pharmaceutical composition
CN111432882A (zh) 2017-10-03 2020-07-17 内瓦卡公司 对乙酰氨基酚-普瑞巴林组合和治疗疼痛的方法
MX2017016884A (es) * 2017-12-19 2019-06-20 Probiomed S A De C V Formulacion farmaceutica estable de una proteina anti-tnfa.
WO2020023310A1 (en) * 2018-07-20 2020-01-30 Williams Eva Compositions of fcrn antibodies and methods of use thereof
WO2024077246A1 (en) * 2022-10-07 2024-04-11 Annexon, Inc. Formulations for anti-c1q antibodies

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6388197A (ja) 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US5900404A (en) 1997-08-15 1999-05-04 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
US20140186361A1 (en) 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
ZA200700947B (en) 2004-07-23 2008-06-25 Genentech Inc Crystallization of antibodies or fragments thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN102924597A (zh) 2005-06-07 2013-02-13 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 抑制TNFα的稳定和可溶的抗体
NZ602498A (en) 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
US9393304B2 (en) * 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
NZ595694A (en) * 2009-05-04 2013-09-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EP3708190A1 (en) * 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
NZ602685A (en) 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
TWI603739B (zh) 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
CN103930124B (zh) 2011-07-01 2021-05-11 生物基因Ma公司 无精氨酸的tnfr：fc-融合多肽组合物及使用方法
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
MX363700B (es) * 2012-03-07 2019-03-29 Cadila Healthcare Ltd Formulaciones farmaceuticas de anticuerpos tnf-alfa.
JP2015519382A (ja) 2012-06-12 2015-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療用抗体のための医薬処方物
CN104768578A (zh) 2012-10-25 2015-07-08 米迪缪尼有限公司 稳定的低粘度抗体配制品
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
EP2914626A2 (en) 2012-11-01 2015-09-09 Abbvie Inc. Stable dual variable domain immunoglobulin protein formulations
CN104707146B (zh) 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
CA2944330A1 (en) 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
ES2572919T3 (es) * 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
PT2946765T (pt) 2014-05-23 2016-11-10 Ares Trading Sa Composição farmacêutica líquida

Also Published As

Publication number Publication date
EP2946767A1 (en) 2015-11-25
CA2948746A1 (en) 2015-11-26
EP2946767B1 (en) 2016-10-05
EP3145488A1 (en) 2017-03-29
IL277241A (en) 2020-10-29
WO2015177059A1 (en) 2015-11-26
LT3145488T (lt) 2020-11-25
HUE050779T2 (hu) 2021-01-28
SI3145488T1 (sl) 2020-10-30
AU2020204269B2 (en) 2020-09-17
AU2020286276B2 (en) 2023-06-01
DK202000038U1 (da) 2020-05-18
PT3145488T (pt) 2020-09-01
EP3145488B1 (en) 2020-07-22
DK202000030U1 (da) 2020-04-28
IL249116A0 (en) 2017-01-31
IL277241B (en) 2022-08-01
HK1231391A1 (zh) 2017-12-22
ES2607489T3 (es) 2017-03-31
DK202000030Y3 (da) 2020-05-26
US10426833B2 (en) 2019-10-01
CN106535935A (zh) 2017-03-22
AU2015263247A1 (en) 2016-12-01
CA3104940A1 (en) 2015-11-26
AU2020286276A1 (en) 2021-01-14
EP3939566A1 (en) 2022-01-19
US20200155677A1 (en) 2020-05-21
CY1124493T1 (el) 2022-03-24
JP2022174082A (ja) 2022-11-22
CN111939257A (zh) 2020-11-17
RS60801B1 (sr) 2020-10-30
HRP20201242T1 (hr) 2020-11-13
ES2815598T3 (es) 2021-03-30
AU2020204269A1 (en) 2020-07-16
CA2948746C (en) 2021-01-12
DK202000038Y3 (da) 2020-07-10
EP3741358A1 (en) 2020-11-25
US20170182162A1 (en) 2017-06-29
IL249116B (en) 2020-09-30
JP2017516848A (ja) 2017-06-22
JP2021107399A (ja) 2021-07-29

Similar Documents

Publication Publication Date Title
BR112016026879A2 (pt) Composição farmacêutica líquida
CL2015000438S1 (es) Dispensador
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
DK3529240T3 (da) Farmaceutiske forbindelser
DK3532029T3 (da) Flydende farmaceutisk sammensætning
DK3171700T3 (da) Infusionsanlæg
BR112016019110A2 (pt) Dispensador
DK3145488T3 (da) Flydende farmaceutiske forbindelse
CL2015001019S1 (es) Ampolleta
DK3145836T3 (da) Dispenseringskapsel
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
DK3199161T3 (da) Farmaceutisk præparat
DK3363428T3 (da) Perfusionsdoseringsform
BR112016030730A2 (pt) Composto
DK3191466T3 (da) Azetidinyloxyphenylpyrrolidinforbindelser
DK3230929T3 (da) Forbedringer til tælleranordninger
DK2992967T3 (da) Medikamentdispenser
DK3164174T3 (da) Lægemiddeladministrationsanordning
DK2907386T3 (da) Væsketransportsystem
DK3215118T3 (da) Lægemiddelanordningsenhed indeholdende quinagolid
DK3288967T3 (da) Farmaceutisk forbindelse
DK3089740T3 (da) Farmaceutisk sammensætning
BR112016027901A2 (pt) Compostos
DK3288966T3 (da) Farmaceutisk forbindelse
DK3441063T3 (da) Flydende thioureylensammensætninger